Note to myself: The resources I reviewed today are listed below. Although very interesting, I don’t believe I need to review them again. If I do want to review the mechanisms of SGLT2 Inhibitors, the best way would be to listen to The Curbsiders‘ Episode #204 podcast while driving in the car. To that end I’ve embedded the podcast here:
The following is from SGLT2 Inhibitors (Gliflozins), updated Jan 15, 2019 from diabetes.co.uk:
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a new group of oral medications used for treating type 2 diabetes The drugs work by helping the kidneys to lower blood glucose levels.
The following drugs belong to the SGLT2 inhibitors class (trade name first, generic name in brackets):
In this post I review some resources on SGLT2 Inhiitors.
I reviewed Renal Effects of SGLT2 Inhibitors: An Update [Link is to the article posted on medscape.com] from Curr Opin Nephrol Hypertens. 2020;29(2):190-198.
And I’ve reviewed the following:
- #204 NephMadness 2020: SGLT2 Inhibitors
APRIL 6, 2020 By HANNAH ABRAMS from The Curbsiders [Link is to the episode list]. - #NephMadness 2020: SGLT2i Region. Posted on March 13, 2020 by in NephMadness. By Dr Harish Seethapathy @BetterCallSeeth
Excerpts from the above coming soon.
